Table 3.
Pathologic cancer categories of patients receiving neoadjuvant therapy for pure squamous cell carcinoma and adenocarcinoma of the esophagus
| Squamous cell carcinoma (n = 2,045) | Adenocarcinoma (n = 5,686) | |
|---|---|---|
| Category | No. (%) | No. (%) |
| ypT | ||
| ypT0 | 604 (30) | 896 (17) |
| ypTis | 6 (0.30) | 13 (0.24) |
| ypT1 | 220 (11) | 752 (14) |
| ypT2 | 363 (18) | 990 (19) |
| ypT3 | 699 (35) | 2,542 (48) |
| ypT4a | 99 (4.8) | 121 (2.3) |
| ypTX | 54 | 372 |
| ypN | ||
| ypN0 | 1,349 (65) | 2,900 (51) |
| ypN+ | 696 (34) | 2,757 (49) |
| ypN1 | 375 (64)* | 1,138 (48)† |
| ypN2 | 157 (27)* | 748 (32)† |
| ypN3 | 54 (9.2)* | 466 (20)† |
| ypNX | 6 | 29 |
| Number of positive nodes | ||
| 0 | 1,343 (70) | 2,900 (55) |
| 1 | 252 (13) | 672 (13) |
| 2 | 123 (6.4) | 466 (8.9) |
| 3 | 60 (3.1) | 273 (5.2) |
| 4 | 50 (2.6) | 206 (3.9) |
| 5 | 31 (1.6) | 133 (2.5) |
| 6 | 16 (0.83) | 136 (2.6) |
| 7 or more | 54 (2.8) | 466 (8.9) |
| Unknown | 116 | 434 |
| ECLNI | 48 (22)§ | 174 (43)¶ |
| Lymphovascular invasion | 211 (28)†† | 736 (37)‡‡ |
| ypM | ||
| ypM0 | 1,931 (94) | 5,334 (94) |
| ypM1 | 114 (5.6) | 352 (6.2) |
| Grade‡ | ||
| ypG1 | 692 (42) | 1,012 (23) |
| ypG2 | 523 (32) | 1,476 (33) |
| ypG3 | 431 (26) | 1,960 (44) |
| ypGX | 399 | 1,238 |
| Location | ||
| ypUpper | 297 (16) | 31 (0.70) |
| ypMiddle | 850 (47) | 141 (3.0) |
| ypLower | 676 (37) | 4,526 (96) |
| ypLocationX | 222 | 988 |
Neoadjuvant pathologic cancer categories of those with adenosquamous and undifferentiated carcinoma are shown in Supporting Information Table S3.
*
Data available for 586 patients.
†
Data available for 2,352 patients.
‡
G4 carcinomas are reported in Supporting Information Table S3.
§
Data available for 221 ypN+ patients.
¶
Data available for 402 ypN+ patients.
††
Data available for 743 patients.
‡‡
Data available for 1,984 patients. ECLNI, extracapsular lymph node invasion.